New Tysabri worries hit Elan
Elan (ELN) dropped 7% after the Irish drug company and Boston-based partner Biogen (BIIB) said their Tysabri drug for multiple sclerosis can harm patients’ livers. The news was first reported by Bloomberg, which cited a note to doctors posted on the Food and Drug Administration’s Web site. The development comes three years after the companies pulled the drug off the market for 16 months so regulators could probe Tysabri’s link to a rare, fatal brain infection. The drug returned to the market in 2006 after the FDA decided the benefits of the drug to MS patients outweighs the risks. The possibility that Tysabri could damage the liver has been reflected in the drug’s label since last month, Bloomberg reported, but the FDA says some doctors may not have known.
The letter adds some to uncertainty overhanging Elan, which is more dependent on Tysabri revenue than its bigger partner Biogen. Rating agency Moody’s recently upgraded Elan, citing Tysabri’s increasing acceptance in the marketplace since its 2006 relaunch. If reports of liver problems slow those gains, though, Elan’s stock - which has doubled over the past year - could be in for a rough patch.
- Biovail unit pleads guilty in kickback probe
- Ex-NBA star a deadbeat?
- Abercrombie profit rises
- Update: Subprime ace backs Icahn in Yahoo fight
- Yahoo’s Cuban sandwich
- Icahn starts Yahoo proxy fight
- Countrywide lawsuit moves forward
- CBS buying CNet in online push
- Icahn going after Yahoo board
- JPMorgan making room for Bear workers
- If Microsoft is allowed to buy Yahoo,... More
- Steve, thanks for the comments. Mos... More
- I was one of those people who lost th... More
- CNET is a great source of online cont... More
- This guy a bully, nothing more nothin... More
- Matt, You are absolutelty right. Br... More
- Yahoo is a dieing entity it needs a f... More
- Daryl The reason the Fed will appr... More
- When is the info going to be disclos... More
- WHY would the government approve a me... More
- Accrued Interest
- Aleph Blog
- Bespoke Investment Group
- Big Picture
- Calculated Risk
- Dealbook
- Econbrowser
- Felix Salmon
- Financial Armageddon
- Footnoted
- FT Alphaville
- Infectious Greed
- Naked Capitalism
- RGE Monitor
- Seeking Alpha
- Information Arbitrage
- Mish's Global Economic Trend Analysis
- Fortune on CNNMoney.com




